Ioachimescu Adriana G, Kelestimur Fahrettin
Department of Medicine, Division of Endocrinology and Molecular Medicine, Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Faculty of Medicine, Department of Endocrinology, Yeditepe University, İstanbul, Türkiye.
Rev Endocr Metab Disord. 2024 Dec;25(6):1003-1011. doi: 10.1007/s11154-024-09909-6. Epub 2024 Sep 23.
Prolactin levels can be influenced by multiple medications primarily through the interaction with dopamine receptors which regulate its secretion. Unlike hyperprolactinemia which has a well-defined clinical phenotype, the effects of hypoprolactinemia beyond inability to lactate are incompletely understood. Recent studies have raised concerns regarding detrimental changes in glucose metabolism, sexual function and psychological profile in patients with low prolactin levels. In contrast with anatomic and genetic etiologies, drug-induced hypoprolactinemia is usually reversible after dose reduction of the offending medication. The most common clinical scenario of drug-induced hypoprolactinemia in the endocrine clinic pertains to patients treated with cabergoline or bromocriptine for prolactin-secreting or other types of pituitary adenomas. Also, data has accumulated regarding hypoprolactinemia in patients receiving aripiprazole for schizophrenia and other psychiatric disorders. These patients warrant careful evaluation for comorbidities. This review aims to increase awareness about the potentially detrimental effects of drug-induced hypoprolactinemia, which should be considered in clinical practice decisions.
催乳素水平主要通过与调节其分泌的多巴胺受体相互作用而受到多种药物的影响。与具有明确临床表型的高催乳素血症不同,低催乳素血症除了导致无法泌乳之外的影响尚未完全明确。最近的研究引发了对催乳素水平低的患者在糖代谢、性功能和心理状况方面有害变化的担忧。与解剖学和遗传学病因不同,药物性低催乳素血症在停用致病药物后通常是可逆的。在内分泌门诊,药物性低催乳素血症最常见的临床情况是接受卡麦角林或溴隐亭治疗催乳素分泌型或其他类型垂体腺瘤的患者。此外,关于接受阿立哌唑治疗精神分裂症和其他精神疾病的患者出现低催乳素血症的数据也在不断积累。这些患者需要仔细评估是否存在合并症。本综述旨在提高对药物性低催乳素血症潜在有害影响的认识,临床实践决策中应考虑这一点。